Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Confusion matrix for ClinicalBERT model. by Ahmed Akib Jawad Karim (20427740)

“…When compared to DistilBERT (66 million parameters) and ClinicalBERT (110 million parameters), LastBERT demonstrated comparable performance, with DistilBERT slightly outperforming it at 87%, and ClinicalBERT achieving 86% across the same metrics. …”

The top 20 candidate drugs demonstrating the most significant sensitivity differences between high- and low-GSRS subjects. by Yu Zhang (12946)

Subjects:

Clinical prognosis analysis of other DE-ERSRGs except PDHB. by Wan-Jing Zhen (20427813)

Subjects:

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Subjects:

Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups. by Cristina Dolciotti (16317330)

Subjects:

Time course of Path Length, LFS and Velocity during postural training. by Cristina Dolciotti (16317330)

Subjects:

Relation of the changes in Y Sway Amplitude and LFS induced by postural training with those in 95% Area. by Cristina Dolciotti (16317330)

Subjects:

Training-induced changes in bipedal stance. by Cristina Dolciotti (16317330)

Subjects:

Between-group differences in 95% Area, Y Sway Amplitude and LFS during postural training. by Cristina Dolciotti (16317330)

Subjects:

Relation between training-related changes in unipedal and bipedal stance. by Cristina Dolciotti (16317330)

Subjects:

Consolidation of training-induced changes in unipedal stance: 95% Area, Y Sway Amplitude and LFS. by Cristina Dolciotti (16317330)

Subjects:

Consolidation of training-induced changes in unipedal stance: Path Length, X Sway Amplitude and Velocity. by Cristina Dolciotti (16317330)

Subjects:

Time course of 95% Area, X and Y Amplitude Sway during postural training. by Cristina Dolciotti (16317330)

Subjects:

Correlations between unipedal and bipedal stance parameters recorded at the beginning of the training and of the control session. by Cristina Dolciotti (16317330)

Subjects: